ANTI-HER2 ANTIBODY-DRUG CONJUGATE Russian patent published in 2019 - IPC A61K31/4745 A61K39/395 A61P35/00 

FIELD: medicine.

SUBSTANCE: group of inventions relates to medicine and concerns an antibody-drug conjugate for treating a tumour and/or cancer. Antitumour compound represented by the following formula:

,

conjugated with an anti-HER2 antibody via a linker, having a structure represented by the following formula: -L¹-L²-L^P-NH-(CH₂)n¹-L^a-(CH₂)n²-C(=O)-, through a thioether bond which forms on the disulphide linking group present in the hinge portion of the anti-HER2 antibody. Group of inventions also relates to a drug for treating a tumour and / or a cancer comprising said conjugate, a salt or hydrate thereof; a pharmaceutical composition for treating a tumour and / or cancer comprising said conjugate, a salt thereof or a hydrate thereof, as an active ingredient, and a pharmaceutically acceptable component of the composition.

EFFECT: group of inventions enables to reduce the dose of the antitumour compound during treatment of a tumour and / or cancer.

37 cl, 64 ex, 14 dwg